Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus

Boston Health Economics, Inc., 20 Fox Rd., Waltham, MA 02451, USA.
Journal of managed care pharmacy: JMCP (Impact Factor: 2.71). 05/2010; 16(4):264-75.
Source: PubMed


Diabetes mellitus requires continuous medical care and patient self-management in order to prevent short-term complications and decrease the risk of long-term complications, which can result in substantial increases in the total economic burden of the disease. Findings from randomized clinical trials have shown that improved glycemic control may reduce the risk of long-term complications as long as a target for hemoglobin A1c is not set below 7% for intensive glycemic control. However, limited data from clinical practice are available regarding the relationship between glycemic control and medical costs associated with diabetes care.
To assess the potential relationships between glycemic levels, diabetes-related hospitalizations, and hospital costs among adult patients with either type 1 or type 2 diabetes mellitus who were assigned to a primary care provider (PCP) in a clinic that was affiliated with a managed care organization (MCO).
A retrospective cohort analysis was conducted using data from approximately 200,000 members of the Fallon Clinic Health Plan who were assigned to a clinic PCP at any time during a 5-year study period beginning January 1, 2002, and ending December 31, 2006. Patients aged 30 years or older with at least 2 medical claims with any listed diagnosis of diabetes mellitus (ICD-9-CM code 250.xx) during the study period and 2 or more A1c values within 1 year of each other during the study period (mean 7.6 tests over 39 months; median=6.8), were identified and stratified into 1 of 5 groups defined by 1% increments of A1c, based on their mean A1c values during the entire study period. A1c data were available only for tests ordered by a clinic provider; tests ordered by other specialists in the MCO's network were absent from the database. The study follow-up period started with each patient's first A1c test (index date) and continued until plan disenrollment, death, or December 31, 2006, whichever was earlier (end date), regardless of when the diagnosis of diabetes mellitus was made. Study measures included the proportion of patients with 1 or more diabetes-related hospitalizations, number of diabetes-related inpatient stays, and the associated estimated hospitalization costs over the follow-up period. Diabetes-related hospitalizations were identified based on a diagnosis, in any of 10 diagnosis fields, for 1 of 16 selected complications of diabetes identified by the authors. Hospital costs were estimated using discharge data (diagnoses and costs calculated from cost-to-charge ratios) contained in the 2004 Healthcare Cost and Utilization Project (HCUP) database and inflated to 2007 dollars using the medical care component of the Consumer Price Index. Multivariate models controlled for age, sex, number of A1c tests, diagnosis of cancer, and follow-up time. A multivariate logistic regression analysis was conducted with the occurrence of at least 1 diabetes-related hospital admission as the dependent variable. In the logistic regression analysis, follow-up time was defined as time from the index date to the date of the first diabetes-related hospitalization, plan disenrollment, death, or the study end date, whichever occurred first. A generalized linear model with a Poisson distribution and a log link was employed to estimate the rate of hospital admissions. In the Poisson regression analysis, follow-up time was defined as duration of the entire study follow-up period and was an offset variable. Costs were estimated using a 2-part model: first, we calculated the probability of having a hospitalization, as determined by the logistic regression above; second, a generalized linear model with a negative binomial distribution and a log link was used to predict the mean cost of diabetes-related hospitalizations only for patients with an inpatient stay, with the duration of the entire study follow-up period as an offset variable. We calculated the mean per patient cost of diabetes-related hospitalizations by multiplying the probability of having a hospitalization (as determined by the first part of the model) by the mean costs for patients who had such admissions (as determined by the second part of the model).
9,887 patients met study selection criteria. Mean A1c level was < 7% for 5,649 (57.1%) patients, 7% to < 8% for 2,747 (27.8%), 8% to < 9% for 1,002 (10.1%), 9% to < 10% for 312 (3.2%), and 10% or more for 177 (1.8%). Over a mean (median) 40 (40) months of follow-up (interquartile range = 30-50 months), 28.7% (n = 2,838) of patients had 1 or more diabetes- related hospital admissions. In the logistic regression analysis, odds of having at least 1 diabetes-related hospital stay did not significantly differ for patients with mean A1c of < 7% compared with patients in most higher mean A1c categories (7% to < 8%, 8% to < 9%, or 9% to < 10%); however, odds of having a diabetes-related hospitalization were significantly higher for patients with mean A1c of 10% or more compared with patients with mean A1c of < 7% (odds ratio = 2.13, 95% confidence interval = 1.36-3.33). In the negative binomial regression analysis of those with at least 1 hospital admission, estimated costs per hospitalized patient increased by mean A1c level. In the Poisson regression analysis, the rate of diabetes-related hospitalizations significantly increased by A1c level (13 per 100 patient-years for patients with mean A1c of < 7% vs. 30 per 100 patient-years for mean A1c of 10% or more when covariates were held at mean levels, P<0.001). In the 2-part model results, adjusted mean estimated costs of diabetes-related hospitalizations per study patient were $2,792 among those with mean A1c of < 7% and $6,759 among those with mean A1c of 10% or more.
In this managed-care plan, the odds of having at least 1 diabetes-related hospitalization were not significantly associated with higher mean A1c except for patients with mean A1c of at least 10%. However, higher mean A1c levels were associated with significantly higher estimated hospitalization costs among those with at least 1 hospitalization and with higher rates of diabetes-related hospital utilization per 100 patient-years.

Download full-text


Available from: Joseph Menzin, Oct 03, 2015
24 Reads
  • Source
    • "Oglesby et al. reported that diabetes related costs were 16% and 20% lower in people with good glycemic control compared with those with fair glycemic control and poor glycemic control [13]. Menzin et al. found that people with a mean A1C ≥ 10% had higher diabetes related hospital costs than those with a mean A1C <7% [14]. It has been estimated that global health expenditures of diabetes and its complications were about 376 billion US dollar (USD) in 2010, while a rise to 490 billion USD in 2030 is anticipated [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the cost of diabetes related micro- and macrovascular complications in Iranian people with type 2 diabetes mellitus. In routine clinical practice, people with type 2 diabetes mellitus were assessed for 10 years at a diabetes care center. The type of medications and clinical data were extracted from patients' documents. Mortality rate and the incidence of micro- and macrovascular complications recorded in patients' documents were analyzed. Cost analysis was comprised of 1) para clinic costs as well as laboratory, medications, clinical visits and nonmedical costs 2) inpatient costs as well as hospital admission costs, disability, and mortality costs. From 1562 people with type 2 diabetes mellitus, a total of 1000 patients with mean duration disease of 11.2 years, who had completed information in their documents, were studied. All people were free from complications at baseline. Mean cumulative incidence of diabetes-related complications over 10 years were 10.9 +/- 3.5 %, 8.0 +/- 3.1 %, 4.6 +/- 1.7 %, 9.1 +/- 3.6 % and 2.3 +/- 0.9 % for peripheral neuropathy and diabetic foot ulcer, nephropathy, ophthalmic complications, cardiovascular disease and death, respectively. People with better glycemic control had less complication and also related expenditures. Average para clinic cost per patient was 393.6 +/- 47.8 and average inpatient cost per patient was 1520.7 +/- 104.5 USD. Our findings demonstrate considerable incidence of diabetes chronic complications and also high health care expenditure for related complications among our patients. As the number of people with diabetes continues to rise, early detection of the disease and implementation of timely and appropriate therapeutic strategies could decrease the burden of diabetes chronic complications and also huge related expenditures.
    Journal of Diabetes and Metabolic Disorders 03/2014; 13(1):42. DOI:10.1186/2251-6581-13-42
  • Source
    • "Older age and higher HbA1c emerged as independent predictors of clinical events in our population, and the relationship was continuous for any HbA1c value. This is an expected result which confirms previous published data [20] [21] [32], clearly showing the importance of the metabolic control in patients with DM. Even an unfavorable lipid profile consisting in high serum LDL cholesterol levels and low HDL cholesterol levels was associated in our experience with adverse clinical events, in line with the results reported by Nichols [33] and UKPD Study 23 researchers [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Left ventricular dysfunction (LVD) in type 2 diabetes mellitus (DM) (DYDA) study is a prospective investigation enrolling 960 with DM without overt cardiac disease. At baseline, a high prevalence of LVD was detected by analysing midwall shortening. We report here the incidence of clinical events in DYDA patients after 2-year follow-up and the frequency of LVD detected at baseline and 2-year evaluation. Systolic LVD was defined as midwall shortening ≤15%, diastolic LVD as any condition different from "normal diastolic function" identified as E/A ratio on Doppler mitral flow between 0.75 and 1.5 and deceleration time of E wave >140ms. Major outcome was a composite of major events, including all-causes death and hospital admissions. During the study period, any systolic/diastolic LVD was found in 616 of 699 patients (88.1%) in whom LVD function could be measured at baseline or at 2 years. Older age and high HbA1c predicted the occurrence of LVD. During the follow-up 15 patients died (1.6%), 3 for cardiovascular causes, 139 were hospitalized (14.5%, 43 of them for cardiovascular causes, 20 for a new cancer). During a 2-year follow-up any LVD is detectable in a large majority of patients with DM without overt cardiac disease. Older age and higher HbA1c predict LVD. All-cause death or hospitalization occurred in 15% of patients, cardiovascular cause was uncommon. Independent predictors of events were older age, pathologic lipid profile, high HbA1c, claudicatio and repaglinide therapy. Echo-assessed LVD at baseline was not prognosticator of events.
    Diabetes research and clinical practice 06/2013; 101(2). DOI:10.1016/j.diabres.2013.05.010 · 2.54 Impact Factor
  • Source
    • "The associated cost for these patients approached $3000/day (Newton & Young, 2006). Menzin et al. (2010) evaluated the relationship between glycemic levels and diabetes-related hospitalization and costs. The authors noted that higher A1C levels were associated with increased hospital costs for those who had been hospitalized at least once and with increased use of hospital services related to diabetes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To provide nurse practitioners (NPs) with a review of the 2012 Standards of Care for the management of hospitalized patients who are hyperglycemic. Data sources: The 2012 American Diabetes Association's (ADA) Standards of Care for the treatment of inpatient hyperglycemia and selected evidence-based articles. Conclusions: Because hyperglycemia occurs at alarming rates in the inpatient setting when hyperglycemia is not controlled, there is a great impact on acute and even chronic conditions. These complications will lead to increased healthcare costs. Implications for practice: It is essential that NPs who care for hospitalized, hyperglycemic patients are aware of the 2012 ADA Standards of Care.
    Journal of the American Academy of Nurse Practitioners 12/2012; 24(12):683-9. DOI:10.1111/j.1745-7599.2012.00770.x · 1.02 Impact Factor
Show more